FDA's "Complete Response" Letter For Byetta LAR Isn't Too Onerous, Amylin Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysts still expect an approval and launch by year end of long-acting exenatide, now branded as Bydureon.